Chart-Typ:
Zeitraum:
| Vervierfacht in einem Monat: Spektakuläre Rallye: Ist Lumen Technologies die neue Super Micro? | © Foto: picture alliance / ASSOCIATED PRESS | Lindsey WassonNur wenige Unternehmen haben so einen kometenhaften Anstieg wie Lumen verzeichnet. Dank milliardenschwerer Aufträge hat sich die Aktie vervierfacht.... ► Artikel lesen |
| Lumen Technologies reports second quarter 2024 results | DENVER, Aug. 6, 2024 /PRNewswire/ -- Lumen Technologies (NYSE: LUMN) reported results for the second quarter ended June 30, 2024.
Driving Commercial Excellence, Stabilizing the Base, and Innovating... ► Artikel lesen |
| +55 Prozent: Lumen Technologies: Kursfeuerwerk durch KI-getriebene Aufträge und Netzausbau | © Foto: picture alliance / ASSOCIATED PRESS | Lindsey WassonDer Kurs von Lumen ist um mehr als 50 Prozent förmlich explodiert, nachdem der Telekomkonzern Aufträge im Milliardenvolumen ankündigte. Nach... ► Artikel lesen |
| RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen |
| RedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2024 Business Highlights | A transformed RedHill:
Numerous potential catalysts
Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. and others: Executing on... ► Artikel lesen |
| RedHill Biopharma Ltd.: RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma | Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childhood cancer cases and 15% of pediatric... ► Artikel lesen |
| Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines | New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen |
| Tonix Pharmaceuticals Holding: New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution | This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations... ► Artikel lesen |
| Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency | The World Health Organization (WHO) released its preferred target product profile (TPP) criteria for mpox vaccines at its Mpox Research and Innovation Scientific Conference held August 29-30 TNX-801... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VSEE HEALTH INC finden Sie auf Wallstreet Online.
